TCOV
KRYS icon

Trust Company of Vermont’s Krystal Biotech KRYS Stock Holding History

Trust Company of Vermont’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.43K Buy
+20
New +$5.98K ﹤0.01% 949
2025
Q4 		$4.93K Hold
20
– – ﹤0.01% 942
2025
Q3 		$3.53K Hold
20
– – ﹤0.01% 965
2025
Q2 		$2.75K Hold
20
– – ﹤0.01% 980
2025
Q1 		$3.61K Hold
20
– – ﹤0.01% 890
2024
Q4 		$3.13K Buy
+20
New +$3.55K ﹤0.01% 913

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Trust Company of Vermont's KRYS Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in Krystal Biotech (KRYS) in Q2 2026: 20 shares worth $7.43K. The stake represents ﹤0.01% of the portfolio and ranks #949 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in KRYS as recently as Q4 2025.

Trust Company of Vermont first reported a position in KRYS in Q4 2024 and has held it in 6 quarters since. 187 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Trust Company of Vermont held 20 shares of Krystal Biotech worth $7.43K as of Q2 2026.
  • Krystal Biotech was a new Trust Company of Vermont position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #949 holding.
  • Trust Company of Vermont first reported a position in Krystal Biotech in Q4 2024 and has held it in 6 quarters since.
  • 187 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.